GlaxoSmithKline begins testing experimental Ebola vaccines on West Africans


Learn more: http://www.naturalnews.com/047462_GlaxoSmithKline_Ebola_vaccines_West_Africans.html#ixzz3Hpe5g6KC


NaturalNews) Now that the general public has been conditioned to accept that Ebola can only be stopped through immediate intervention with magic drugs and vaccines from the West, British vaccine giant GlaxoSmithKline (GSK) is readying to begin tests on an experimental Ebola vaccine, which reports indicate will be given to unsuspecting healthcare workers in Mali.

Though there have been no reported Ebola cases in Mali, GSK is fast-tracking its vaccine, known as cAd3-ZEBOV, with the blessing of the World Health Organization (WHO), for rapid approval in early 2015. Normally, the preliminary testing process alone would take up to a year, but ongoing Ebola propaganda has facilitated a "lightning speed" approval process that appears to have been the goal of the Ebola "crisis" all along.

According to FierceVaccines, a total of 40 healthcare workers in Mali will receive the experimental Ebola vaccine, which GSK developed in conjunction with the Vaccine Research Center (VRC) and the National Institute of Allergy and Infectious Diseases (NIAID). Mali's Center for Vaccine Development and Ministry of Health are both onboard as well.

The vaccine "uses a chimpanzee cold virus vector containing two ebolavirus gene segments that switch on a protein to activate an immune response in the body," explains FierceVaccines. "A parallel trial in Gambia is expected to begin soon."


Canadian vaccine company also prepping experimental Ebola jab for use on Americans
This vaccine party is being joined by Canada's NewLink Genetics, which has reportedly entered Phase I trials for its own Ebola jab, known as rVSV-ZEBOV. Similar to cAd3-ZEBOV, rVSV-ZEBOV contains a weakened vesicular stomatitis virus as its vector, which is intended to trigger an immune response against Ebola.

In a statement, NewLink announced that 20 vials of the vaccine will be administered to human guinea pigs in the U.S. Earlier this month, the company also indicated that participants in Germany, Switzerland and an unnamed African country that has not yet seen any cases of Ebola would also be receiving the experimental vaccine.

Data from the Phase I trial in Maryland will be made available in December 2014, claims the company.

"Both vaccines are flying through the regulatory process at lightning speed," says FierceVaccines. "Typically, it would take 6 to 11 months to move an experimental vaccine from preclinical testing into clinical trials. But the jabs are being fast-tracked by the World Health Organization in an effort to halt the spread of the disease as fast as possible."


Vaccine companies have no idea if humans will be harmed by experimental Ebola vaccines
Part of NewLink's statement admits that those to whom the vaccines will be given could be harmed by them. The purpose of the trials, after all, is to "assess [their] safety, determine the appropriate dosage and identify any side effects."

Some believe that the vaccines themselves will be what propels the Ebola outbreak to new threatening levels, potentially transforming a regionalized epidemic into a full-scale global pandemic. Both of the vaccines in question contain live viruses, after all, which are known to shed for days or even weeks, infecting others who come into direct contact with the injected.

It could take years before the full scope of the damage caused by these experimental vaccines is known. Drug giant Pfizer only recently made its first compensatory payments to families of Nigerian children who were injured by an experimental drug it tested there back in 1996. According to BBC News, 11 children died from the anti-meningitis drug Trovan, and dozens of others were left permanently disabled.


Learn more: http://www.naturalnews.com/047462_GlaxoSmithKline_Ebola_vaccines_West_Africans.html#ixzz3HpdtYROn